As previously communicated, Lumito's ambition and plan has been to offer product for researchers use only by the end of 2022. Employees and production partners have together set the plan and worked hard and focused on fulfilling the ambition, which has been deemed fully realistic until now. Lumito therefore wishes to inform that the launch of a completed product will be slightly delayed. The company's estimation is that the launch will take place in the first part of 2023.
The reasons for the delay are:
– Component and material shortages, which have resulted in delayed deliveries from subcontractors.
– Following verification of the final design, a decision has now been made to make minor design modifications to optimize the product.
– The above points have in addition delayed the availability and time of testing institutes for independent EMC and safety testing for the forthcoming CE marking. Even if a product launch for research laboratories only means self-certification, these tests must be conducted.
"The finished product will be slightly delayed, but we will still offer the expanding market a well-functioning, sustainable CE-marked product that meets the need for better solutions in research. SCIZYS delivers great images that meet market requirements, both in conventional brightfield technology and with our unique UCNP (Upconverting Nano Particles) labeling. The pre-launch that was initiated earlier this year, to strengthen the awareness of SCIZYS and our innovative technology, will continue and be intensified as planned in the coming months", comments Lumito's CEO Mattias Lundin.
This information is information that Lumito AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out in this press release, at 3:30 p m on October 30, 2022.
For further information, please contact:
Lumito's CEO, Mattias Lundin
Ph: +46 76 868 45 09
Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, of which digital pathology remains the focus of Lumito and the initial launch in researchers use only. The company is a spin-off from a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en.
The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: 08-503 015 50.